United States Food and Drug Administration (USFDA) has completed a GMP Inspection of Lupin’s API manufacturing facility located at Dabhasa, India. The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations. This accomplishment underscores the company’s unwavering dedication to maintaining the highest standards of quality and compliance in all aspects of its operations.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
